Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure.

@article{Nymo2017LimitedAV,
  title={Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure.},
  author={St{\aa}le Haugset Nymo and P. A. Aukrust and John Kjekshus Kjekshus and John J V McMurray and John G. F. Cleland and John Wikstrand and Pieter Muntendam and Ursula Wienhues-Thelen and Roberto C. Latini and Erik Tandberg Askevold and J{\o}rgen A. Gravning and Christen Peder Dahl and Kaspar Broch and Arne Yndestad and Lars Gullestad and Thor Ueland},
  journal={JACC. Heart failure},
  year={2017},
  volume={5 4},
  pages={
          256-264
        }
}
OBJECTIVES This study sought to evaluate whether a panel of biomarkers improved prognostication in patients with heart failure (HF) and reduced ejection fraction of ischemic origin using a systematized approach according to suggested requirements for validation of new biomarkers. BACKGROUND Modeling combinations of multiple circulating markers could potentially identify patients with HF at particularly high risk and aid in the selection of individualized therapy. METHODS From a panel of 20… CONTINUE READING
BETA
67
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Pentraxin 3 in Cardiovascular Disease

VIEW 1 EXCERPT
CITES BACKGROUND

Cholesterol and Heart Failure: Is There an Important Connection?

  • Journal of the American College of Cardiology
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.

  • European journal of heart failure
  • 2012
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…